{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:32Z","timestamp":1787261012795,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101228","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:02:12Z","timestamp":1783602132000},"page":"101228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High-dose-rate monotherapy for localised prostate Cancer: A two-implant approach with median 13\u00a0years follow-up"],"prefix":"10.1016","volume":"60","author":[{"given":"Christopher","family":"Best","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Spier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos","family":"Baltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101228_bb0005","series-title":"Prostate Cancer Statistics","author":"Prostate Cancer Statistics | World Cancer Research Fund","year":"2026"},{"issue":"4","key":"10.1016\/j.ctro.2026.101228_bb0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ijc.31102","article-title":"Summary statement on screening for prostate cancer in Europe","volume":"142","author":"Heijnsdijk","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2009.01.062","article-title":"Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I\/II dose escalation study","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ctro.2026.101228_bb0020","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.25467","article-title":"Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer","volume":"117","author":"Alicikus","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctro.2026.101228_bb0025","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijrobp.2010.05.042","article-title":"Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience","volume":"81","author":"Sylvester","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2026.101228_bb0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00066-012-0078-3","article-title":"Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients","volume":"188","author":"Goldner","year":"2012","journal-title":"Strahlentherapie und Onkologie\u00a0: Organ der Deutschen Rontgengesellschaft [et al]"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0360-3016(01)01758-8","article-title":"Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer","volume":"52","author":"Galalae","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2026.101228_bb0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0360-3016(98)00097-2","article-title":"High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report","volume":"41","author":"Mate","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2026.101228_bb0045","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","article-title":"High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity","volume":"110","author":"Hoskin","year":"2014","journal-title":"Radiotherapy oncology: Journal European Soc Therapeutic Radiology Oncology"},{"issue":"7","key":"10.1016\/j.ctro.2026.101228_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2017.02.015","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer: review of the current status","volume":"29","author":"Tselis","year":"2017","journal-title":"Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2026.101228_bb0055","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ctro.2026.101228_bb0065","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","article-title":"Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes","volume":"60","author":"Zelefsky","year":"2011","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0070","article-title":"High-dose-rate brachytherapy for prostate cancer: rationale, current applications, and clinical outcome","volume":"5","author":"Strouthos","year":"2022","journal-title":"Cancer reports (Hoboken, N.J.)"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.meddos.2021.08.003","article-title":"Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT","volume":"47","author":"Chavez","year":"2022","journal-title":"Med Dosim"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-8-115","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients","volume":"8","author":"Tselis","year":"2013","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101228_bb0085","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.ctro.2026.101228_bb0090","doi-asserted-by":"crossref","first-page":"8092","DOI":"10.3390\/curroncol30090587","article-title":"The current trend of radiation therapy for patients with localized prostate Cancer","volume":"30","author":"Numakura","year":"2023","journal-title":"Current Oncology"},{"key":"10.1016\/j.ctro.2026.101228_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770959","article-title":"High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate Cancer. Oncological outcomes after a median 15-year follow-up","volume":"11","author":"Behmueller","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101228_bb0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/jcb.2020.101685","article-title":"High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-Centre experience","volume":"12","author":"Soatti","year":"2020","journal-title":"J Contemporary Brachytherapy"},{"issue":"3","key":"10.1016\/j.ctro.2026.101228_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5114\/jcb.2021.105846","article-title":"High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center","volume":"13","author":"Johansson","year":"2021","journal-title":"J Contemporary Brachytherapy"},{"key":"10.1016\/j.ctro.2026.101228_bb0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiotherapy and oncology\u00a0: J European Soc Therapeutic Radiology Oncology"},{"issue":"4","key":"10.1016\/j.ctro.2026.101228_bb0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ijrobp.2015.05.044","article-title":"High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate Cancer: clinical results for a median 8-year follow-up","volume":"94","author":"Yoshioka","year":"2016","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101228_bb0125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate Cancer: 10-year results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2026.101228_bb0130","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ijrobp.2010.10.015","article-title":"High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer","volume":"81","author":"Demanes","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101228_bb0135","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.brachy.2010.02.127","article-title":"Interstitial high-dose-rate brachytherapy as monotherapy for early stage prostate Cancer: median 8-year results in 301 patients","volume":"9","author":"Mark","year":"2010","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.ctro.2026.101228_bb0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101228_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110381","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: a 9-year update","volume":"198","author":"Hudson","year":"2024","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.juro.2011.09.050","article-title":"High dose brachytherapy as monotherapy for intermediate risk prostate cancer","volume":"187","author":"Rogers","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2026.101228_bb0155","doi-asserted-by":"crossref","unstructured":"P. Hoskin et al., \u2018High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence\u2019, Int J Radiat Oncol Biol Phys, vol. 82, no. 4, pp. 1376\u20131384, 2012, doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2011.04.031\"https:\/\/doi.org\/10.1016\/j.ijrobp.2011.04.031\".","DOI":"10.1016\/j.ijrobp.2011.04.031"},{"issue":"2","key":"10.1016\/j.ctro.2026.101228_bb0160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijrobp.2010.02.013","article-title":"Monotherapeutic high-dose-rate brachytherapy for prostate Cancer: five-year results of an extreme Hypofractionation regimen with 54 Gy in nine fractions","volume":"80","author":"Yoshioka","year":"2011","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctro.2026.101228_bb0165","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.radonc.2020.12.021","article-title":"Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial","volume":"156","author":"Corkum","year":"2021","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101228_bb0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results","volume":"85","author":"Zamboglou","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.ctro.2026.101228_bb0175","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clon.2013.04.009","article-title":"Brachytherapy: current status and future strategies \u2014 can high dose rate replace low dose rate and external beam radiotherapy?","volume":"25","author":"Morton","year":"2013","journal-title":"Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101228_bb0180","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e3181b9cd2f","article-title":"High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer","volume":"33","author":"Martinez","year":"2010","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101228_bb0185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1442-2042.2012.03125.x","article-title":"Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy","volume":"20","author":"Komiya","year":"2013","journal-title":"Int J Urology\u00a0: Official J Japanese Urological Association"},{"issue":"1","key":"10.1016\/j.ctro.2026.101228_bb0190","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1748-717X-9-122","article-title":"Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer","volume":"9","author":"Ghadjar","year":"2014","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101228_bb0195","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2026.101228_bb0200","doi-asserted-by":"crossref","DOI":"10.1097\/01.ju.0000169136.55891.21","article-title":"A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy","author":"Vargas","year":"2005","journal-title":"J Urol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:24:45Z","timestamp":1787257485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S2405630826001230"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101228","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose-rate monotherapy for localised prostate Cancer: A two-implant approach with median 13\u00a0years follow-up","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101228"}}